23andMe

23andMe is a leading consumer genetics and research company based in Sunnyvale, CA. Since its establishment in 2006, the company has been committed to enabling individuals to access, comprehend, and capitalize on the human genome. Notably, 23andMe stands out as the sole company possessing multiple FDA authorizations for genetic health risk reports, thereby pioneering direct access to genetic information. With a remarkable 80 percent of its customer base volunteering to engage, the company has forged the world’s largest crowdsourced platform for genetic research, resulting in over 180 publications that delve into the genetic foundations of diverse diseases, conditions, and traits.

Furthermore, 23andMe boasts the Therapeutics group, leveraging its research platform to drive drug discovery programs rooted in human genetics across an array of disease sectors, such as oncology, respiratory, and cardiovascular diseases. The company has received recognition as one of the San Francisco Chronicle's Top Workplaces and has been hailed as one of Comparably's Best Places to Work in 2022. CEO Anne Wojcicki has been acknowledged for her leadership, being named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in both 2021 and 2022. The latest milestone for 23andMe involves a $74.70M Private Equity investment on 21 February 2025, with investment coming from Anne Wojcicki and Matthew Holt.

For further details, visit www.23andMe.com.